

San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Centre
December 4-8, 2018

Abstracts

Wednesday, December 5, 2018

CCTG MA.38 - Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer

Time: Wednesday, December 5, 2018: 5:00 PM

Location: Stars at Night Ballroom 1 & 2

Type: Poster

Session: Spotlight Session: Developmental Therapeutics (5:00 – 7:00 PM)

Abstract: *Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)*

Abstract #: PD1-10

Authors: Parulekar WR, Joy AA, Gelmon K, Mates M, Desbiens C, Clemons M, Taylor S, Lemieux J, Bartlett J, Whelan T, Ayoub J-P, Cescon D, Bordeleau L, Rahim Y, Winch C, Chen BE

Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_359&terms=

SWOG S0307/CCTG MAC.9 - Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

Time: Wednesday, December 5, 2018: 5:00 PM

Location: Hall 1

Type: Poster

Session: Poster Session 1: Treatment: Adjuvant Therapy — Other (5:00 – 7:00 PM)

Abstract: *Statin use, site of recurrence, and survival among post-menopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307)*

Abstract #: P1-17-03

Authors: Kizub D, Miao J, Stopeck A, Thompson P, Paterson AH, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow W, Hortobagyi GN, Gralow JR

Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_741&terms=

Thursday, December 6, 2018

CCTG MA.31 - A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer

Time: Thursday, December 6, 2018: 7:00 AM
Location: Stars at Night Ballroom 1 & 2
Type: Poster
Session: Spotlight Session: Next Steps in HER2 Targeted Therapy (7:00 – 9:00 AM)
Abstract: ***Higher serum PD-L1 predicts for increased overall survival to lapatinib vs trastuzumab in the phase 3 CCTG MA.31 trial***
Abstract #: PD3-10
Authors: Moku PR, Shepherd LE, Ali SM, Leitzel K, Parulekar WE, Zhu L, Virk S, Nomikos D, Aparicio S, Gelmon KA, Drabick JJ, Cream L, Halstead SE, Umstead T, Mckeone D, Maddukuri A, Polimera HV, Ali A, Poulouse J, Pancholy N, Spiegel H, Nagabhairu V, Chen BE, Lipton A
Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1290&terms=

GENERAL

Time: Thursday, December 6, 2018: 10:00 AM
Location: Hall 3
Type: Oral Session
Session: Oral Session: General Session 3 (9:30 – 11:30 AM)
Abstract: ***Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women***
Abstract #: GS3-03
Authors: Gray R, Early Breast Cancer Trialists' Collaborative Group
Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1589&terms=

GENERAL

Time: Thursday, December 6, 2018: 3:30 PM
Location: Hall 3
Type: Oral Session
Session: Oral Session: General Session 4 (3:15 – 5:00 PM)
Abstract: ***Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials***
Abstract #: GS4-02
Authors: Dodwell D, Taylor C, McGale P, Coles C, Duane F, Gray R, Kühn T, Hennequin C, Oliveros S, Wang Y, Overgaard J, Poortmans P, Whelan T
Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1158&terms=

Friday, December 7, 2018

GENERAL

Time: Friday, December 7, 2018: 7:00 AM
Location: Hall 1
Type: Poster
Session: Poster Session 4: Treatment: Adjuvant endocrine Therapy (7:30 – 9:00 AM)
Abstract: *Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer*
Abstract #: P1-14-03
Authors: Ethier J-L, Parulekar W, Shepherd L, Summers L, Strasser-Weippl K, Tu D, Amir E
Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1279&terms=

ECOG PACCT-1/ MAC.12 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

Time: Friday, December 7, 2018: 3:45 PM
Location: Hall 3
Type: Oral
Session: Oral Session: General Session 6 (3:15 – 5:00 PM)
Abstract: *Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results*
Abstract #: GS6-03
Authors: Wagner LI, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos R, Gareen I, McCaskill-Stevens W, Cella D, Sparano JA, Sledge, Jr. GW, On behalf of the TAILORx Study Team
Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_947&terms=

Saturday, December 8, 2018

CCTG MAP.3 - A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Time: Saturday, December 8, 2018: 7:00 AM
Location: Hall 1
Type: Poster
Session: Poster Session 6: Epidemiology, Risk, and Prevention: Prevention — Clinical Trials (7:30 – 9:00 AM)
Abstract: *Association between the UGT2B17 gene deletion, exemestane metabolites and vasomotor QOL in women participating on the MAP3 prevention trial*
Abstract #: P6-13-05
Authors: Richardson H, Knight B, Chen G, Luo S, Massey T, Goss PE, Lazarus P
Link: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1101&terms=